Fig. 5.

Clustered Regularly Interspaced Short Palindromic Repeats/Associated Systems for corneal disorders. The CRISPR/Cas9 system is revolutionizing the way in which scientists investigate disease models and therapeutic modalities. The combined use of CRISPR/Cas9 technology with nanocarriers, recombinant adeno-associated virus (rAAV), or lentivirus vectors will afford multiple gene therapy that is particularly beneficial to inherited corneal disorders. Reprinted with permission from Raikwar SP et al. World J. of Transl. Med. 2016; 5(1):1–13.